GPC3 and B-cell chronic lymphocytic leukemia: This hypothesis was supported by the results showing that the GPC3 antibody HS20, which recognizes the heparan sulphate chains and inhibits the activity of GPC347, abolished the effect of TFPI on the expression of CXCR7 and the migration of CLL cells.